News Room
News Room
News Room
Groundbreaking Achievements and Pivotal Milestones for Paragon and its Portfolio Companies
In 2024, Paragon and its portfolio companies achieved remarkable research and development progress, driving innovative solutions for patients with critical unmet needs. [...]
Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study
Topline data from Phase 3 study in patients with Tourette syndrome shows statistical significance between ecopipam and placebo for both the primary efficacy endpoint [...]
Emalex Biosciences Named “Neuroscience Therapeutics Company Of The Year” by BioTech Breakthrough
Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industries CHICAGO, November 19, 2024 – Emalex Biosciences was named “Neuroscience [...]
Article Highlights Positive Study Results Presented at AAN Annual Meeting
By Mary Beth Nierengarten, April 1, 2024 – Ecopipam reduced the number of tics and the level of daily interference they cause in children [...]
Harmony Biosciences Ranked Among Top 25 Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500™
Ranking attributed to 7,204% growth from fiscal year 2019 to 2022 PLYMOUTH MEETING, Pa., Nov. 15, 2023 /PRNewswire/ – Harmony Biosciences Holdings, Inc. ("Harmony" [...]
Evozyne Announces $81 Million Financing Round to Advance Generative AI for Therapeutic Discovery and Drug Development
New investor OrbiMed expects platform to reduce development time for novel treatments and therapeutic approaches CHICAGO - BUSINESS WIRE, September 27, 2023 – Evozyne [...]
